ResMed, the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today launched AirSenseTM 11 in India, the company’s next-generation Continuous Positive Airway Pressure (CPAP) device designed to make it easier for individuals with Obstructive Sleep Apnea (OSA) to start and stay on therapy.
The ResMed 2024 Global Sleep Survey, conducted across 17 markets worldwide, revealed that a striking 46% of respondents were found to have been diagnosed with a history of OSA. However, 33% of these respondents either chose not to start treatment, or start their own methods to combat their sleep difficulties. As the most common sleep-related breathing disorder, OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common sign being snoring.
To address the rising cases of sleep apnea in India, ResMed introduced the AirSenseTM 11, which includes new features like Personal Therapy Assistant and Care Check-In designed to provide tailored guidance to PAP users, helping ease them into therapy and comfortable nightly use. Other features include the availability of remote software updates so users can enjoy the latest version of these tools every night.
“AirSenseTM 11’s new tailored features along with our myAir patient engagement app help give people the support they need to use CPAP – the gold standard for treating sleep apnea – comfortably and confidently every night,” said Sandeep Gulati, General Manager, ResMed, India, South Asia. “The importance of quality sleep cannot be overstated – and yet it is hard to achieve. The AirSenseTM 11, with its full suite of digital health features to make it easier for people to not only start, but stay on CPAP therapy, helping people who suffer from sleep apnea breathe better, sleep better and live better lives.
ResMed’s most innovative CPAP device yet, the AirSenseTM 11 features:
- Personal Therapy Assistant: An intuitive, step-by-step tutorial that users can access available through the myAir app to help users set up their devices, reducing setup time and acclimating to therapy pressure that improves ease of use.
- Care Check-In: Provides personalised feedback and guidance based on an individual’s responses to questions like, “How is your therapy?” and “How sleepy did you feel this week?” This feature is accessible via the myAir app and the device screen. With the user’s consent, healthcare providers can see their patients’ responses in AirView, providing another fast, virtual way to monitor patients.
- Test Drive: Allows users to try different pressure levels, helping them acclimate to therapy more comfortably.
- Sleek Design: Features an intuitive touchscreen interface for ease of use during therapy.
- Proprietary therapy algorithms: Auto-adjusting PAP therapy (AutoSet or APAP) delivers customised breath-by-breath therapy, including specialised settings for women through the AutoSet for Her mode.
- Over-the-Air Upgrades: Software enhancements delivered directly to the device, ensuring users have access to the latest features, improving user experience and therapy outcomes.
The AirSenseTM 11 includes access to myAir (ResMed’s patient engagement app) and AirView (ResMed’s remote monitoring platform for clinicians), which help bring overall patient adherence as high as 87%. The myAir app tracks the time patients spend using CPAP therapy, the number of sleep apnea events per hour, mask leaks, and the number of times a mask was removed, providing nightly data on breathing, coaching tips, and support directly to their phone.
AirView provides a secure, cloud-based patient management system for online patient monitoring that enables healthcare professionals to access patient data quickly, share clinical insights with other health professionals, improve care and reduce costs related to patient follow-up.
